1,4-Bis((4-chlorophenyl)(phenyl)methyl)piperazine

Catalog No. :
ACXZBK106
CAS No. :
346451-15-8
Molecular Formula :
C30H28Cl2N2
Molecular Weight :
487.47

IUPAC Name:1,4-bis((4-chlorophenyl)(phenyl)methyl)piperazine

1,4-Bis((4-chlorophenyl)(phenyl)methyl)piperazine structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
No pack options available.

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name1,4-Bis((4-chlorophenyl)(phenyl)methyl)piperazine
IUPAC Name1,4-bis((4-chlorophenyl)(phenyl)methyl)piperazine
Molecular FormulaC30H28Cl2N2
Molecular Weight487.47
SMILESClC1=CC=C(C(N2CCN(C(C3=CC=C(Cl)C=C3)C4=CC=CC=C4)CC2)C5=CC=CC=C5)C=C1
InChI KeyZHKWYPRSELVIIG-UHFFFAOYSA-N
Synonym346451-15-8 | 1,4-BIS[(4-CHLOROPHENYL)PHENYLMETHYL]PIPERAZINE DIHYDROCHLORIDE | Cetirizine Impurity D DiHCl | 856841-95-7 | 1,4-Bis((4-chlorophenyl)(phenyl)methyl)piperazine dihydrochloride | 1,4-bis[(4-chlorophenyl)-phenylmethyl]piperazine;dihydrochloride | C30H30Cl
CAS No.346451-15-8
PubChem CID24720891

Safety Data

Pictogram
Harmful or irritant
Signal Word
Warning
Hazard Statement(s)
H302-H315-H319
Precautionary Statement(s)
P264-P270-P280-P301+P312+P330-P302+P352-P305+P351+P338-P332+P313-P337+P313-P362+P364-P501

Synthetic Route by SureRoute

1. ACXZBK106 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACSRTI108 route compound structure diagram
    ACSRTI108303-26-4 In Stock
  4. Then
  5. ACXZBK106 route product structure diagram
    ACXZBK106346451-15-8
Inquiry

2. ACXZBK106 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACSRTI108 route compound structure diagram
    ACSRTI108303-26-4 In Stock
  4. Then
  5. ACXZBK106 route product structure diagram
    ACXZBK106346451-15-8
Inquiry

Comments (0)